Nadir CA125 concentration as a prognostic indicator in ovarian cancer

Nature Clinical Practice Oncology

Volumn 2, Issue 6, 2005, Pages 288-289

  Baron, Andre T ^a   Maihle, Nita ^b  

^a UNIVERSITY OF KENTUCKY COLLEGE OF PUBLIC HEALTH   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CA125; Chemotherapy; Epithelial ovarian carcinoma; Prognosis; Tumor marker

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; PACLITAXEL; TUMOR MARKER;

ANTIGEN DETECTION; CANCER RELAPSE; HUMAN; OUTCOMES RESEARCH; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; SHORT SURVEY;

EID: 21344466560     PISSN: 17434254     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncponc0178     Document Type: Short Survey

References (3)

1. Meyer T and Rustin GJ (2000) Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer 82: 1535-1538
2. Fritsche HA and Bast RC (1998) CA 125 in ovarian cancer: advances and controversy. Clin Chem 44: 1379-1380
3. Rustin GJS et al. (2001) Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol 19: 4054-4057